Why is fair value unavailable for GB Sciences Inc (OTC-GBLX) stock?

A reliable fair value estimate is not currently available for GB Sciences Inc (OTC-GBLX). This generally means the latest dataset does not contain enough valid inputs for the valuation models supported by PriceToWorth. The site does not substitute zero or publish an unsupported estimate; availability may change when updated financial data or applicable model inputs become available.

How is the financial health of GB Sciences Inc?

The current financial health read for GB Sciences Inc (OTC-GBLX) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is GB Sciences Inc's next earnings date?

The next earnings date currently listed for GB Sciences Inc (OTC-GBLX) is November 23, 2026.

Does GB Sciences Inc (OTC-GBLX) pay dividends?

The latest available data indicates no current dividend yield for GB Sciences Inc (OTC-GBLX).

What is the market capitalization of GB Sciences Inc?

The current market capitalization listed for GB Sciences Inc is 105.881 K.

What is the enterprise value of GB Sciences Inc?

The current enterprise value listed for GB Sciences Inc is 2.15 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for GB Sciences Inc?

The ticker symbol for GB Sciences Inc is OTC-GBLX, and the stock is listed on OTC Markets.

Where is GB Sciences Inc (OTC-GBLX) listed?

GB Sciences Inc (OTC-GBLX) is listed on OTC Markets.

What is the debt-to-total-capital ratio for GB Sciences Inc?

The current debt-to-total-capital ratio listed for GB Sciences Inc is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

GB Sciences Inc (GBLX) Fair Value & Stock Analysis

GB Sciences Inc (GBLX)

GB Sciences, Inc. is a healthcare company focused on plant-based research and biopharmaceutical drug development. The company develops cannabis-inspired medicines and complex therapeutic mixtures aimed at the prescription drug market. Its intellectual property and development programs span several therapeutic areas, including Parkinson’s disease, neuropathic pain, chronic pain, cytokine release syndrome, stress, anxiety, depression, and cardiovascular conditions, with work described as being in the pre-clinical animal stage. The company was previously known as Growblox Sciences, Inc. and adopted its current name in October 2016. GB Sciences is based in Las Vegas, Nevada, and its common stock trades on OTC Markets under the symbol GBLX.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Analyst Price Target	Analyst Target Upside/Downside	Overall Financial Health	Dividend Yield	Next Earnings Date	Market Cap	Enterprise Value	Total Debt / Total Capital
OTC-GBLX	Not available	Not available	Not available	Weak	0.0%	November 23, 2026	105.881 K	2.15 M	0.0%